FilingIndex
← The Wire
IRDNasdaq

Opus Genetics, Inc.

Pharmaceutical Preparations · DE · CIK 1228627

Opus Genetics develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases

red 8-K · 90d
$334M
Market cap
$4.06
Last close
+1.5%
1D
-0.5%
5D
824K
Volume
Price · last 39 sessions-22.2%
May 4L $3.71 · H $5.36Jun 29
397
Total filings
Jun 16, 2026
Last filing
12/31
Fiscal year end
8-KReg FD DisclosureJun 16, 20268-KReg FD DisclosureJun 16, 2026SC 13D/ASC 13D/AMay 20, 202610-Q10-QMay 12, 20268-KResults of OperationsMay 12, 20268-KNew Debt / ObligationApr 24, 20268-KShareholder VoteApr 22, 20268-KExecutive ChangeApr 7, 20268-KMaterial Agreement · Equity IssuanceApr 7, 2026DEF 14ADEF 14AMar 23, 202610-K10-KMar 12, 20268-KResults of OperationsMar 10, 20268-KMaterial Agreement · Results of OperationsFeb 19, 20268-KReg FD DisclosureJan 12, 20268-KReg FD DisclosureJan 8, 20268-KCompany UpdateDec 19, 2025SC 13D/ASC 13D/ADec 11, 202510-Q10-QNov 12, 20258-KResults of OperationsNov 12, 20258-KMaterial Agreement · Company UpdateNov 6, 20258-KReg FD Disclosure · Company UpdateNov 6, 2025424B5424B5Nov 6, 20258-KReg FD Disclosure · Company UpdateSep 30, 20258-KExecutive Change · Reg FD DisclosureSep 2, 20258-KEquity IssuanceAug 25, 202510-Q10-QAug 13, 20258-KResults of OperationsAug 13, 20258-KMaterial Agreement · Reg FD DisclosureJul 23, 2025424B5424B5Jun 26, 20258-KCompany UpdateJun 26, 20258-KExecutive ChangeJun 25, 20258-KReg FD DisclosureJun 23, 20258-KMaterial AgreementJun 20, 202510-Q10-QMay 15, 20258-KResults of OperationsMay 15, 20258-KShareholder VoteMay 1, 2025DEFA14AADDITIONAL DEFINITIVE PROXY SOLICITATING MATERIALSApr 14, 2025DEFA14AADDITIONAL DEFINITIVE PROXY SOLICITATING MATERIALSApr 11, 2025DEFA14AADDITIONAL DEFINITIVE PROXY SOLICITATING MATERIALSApr 10, 2025DEFA14AADDITIONAL DEFINITIVE PROXY MATERIALApr 7, 20258-KAgreement TerminatedApr 4, 2025424B5PROSPECTUS SUPPLEMENTApr 4, 202510-K10-KMar 31, 20258-KResults of OperationsMar 31, 20258-KEquity Issuance · Company UpdateMar 24, 2025424B5424B5Mar 24, 20258-KResults of OperationsMar 20, 2025424B5424B5Mar 20, 20258-KBylaw Amendment · Company UpdateMar 20, 20258-KCompany UpdateMar 4, 20258-KExecutive ChangeJan 24, 20258-KCompany UpdateJan 23, 20258-KCompany UpdateJan 14, 2025424B5424B5Jan 13, 20258-K/ACompany UpdateJan 7, 202510-Q10-QNov 12, 20248-KResults of OperationsNov 12, 2024SC 13DSC 13DOct 29, 20248-KExecutive Change · Material AgreementOct 22, 202410-Q10-QAug 13, 20248-KResults of OperationsAug 13, 20248-KBylaw Amendment · Shareholder VoteJun 13, 202410-Q10-QMay 10, 20248-KReg FD DisclosureMay 10, 20248-KResults of OperationsMay 10, 2024DEFA14ADEFA14AApr 29, 2024DEF 14ADEF 14AApr 29, 20248-KExecutive ChangeApr 17, 20248-KReg FD DisclosureMar 27, 202410-K10-KMar 8, 20248-KResults of OperationsMar 8, 20248-KExecutive ChangeFeb 16, 20248-KExecutive ChangeDec 6, 20238-KExecutive Change · Reg FD DisclosureNov 27, 202310-Q10-QNov 13, 20238-KResults of OperationsNov 13, 20238-KReg FD Disclosure · Company UpdateNov 2, 20238-KExecutive Change · Reg FD DisclosureNov 1, 20238-KCompany UpdateSep 27, 2023424B5424B5Aug 14, 2023

Insider Activity

In the 90 days to Mar 16, 2026: 1 insider bought $324K · 4 sold $181K.

DateInsiderActionSharesPriceValue
Mar 16, 2026Magrath GeorgeChief Executive OfficerSell24,438$5.21$127K
Mar 16, 2026Schachle Joseph KChief Operating OfficerSell3,719$5.25$20K
Mar 16, 2026Jayagopal AshwathChief Scientific & Dev. Ofc.Sell3,719$5.12$19K
Mar 16, 2026Zaremba Rabourn AmyHead of Fin. Quality AssuranceSell2,816$5.25$15K
Dec 29, 2025Gallagher CamDirectorBuy83,000$1.97$164K
Dec 29, 2025Gallagher CamDirectorBuy81,000$1.98$160K
Dec 9, 2025Foundation Fighting Blindness Retinal Degeneration FundDirector,OtherSell4,000,000$2.15$8.6M

Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.

Similar companies

Comparable business profile · signals at a glance